News

Ferring and GenerationS Summarize the Selection of Innovative Projects in Reproductive Health and Fertility

29.04.2020

Swiss biopharmaceutical company — Ferring Pharmaceuticals — summed up the selection of technological projects based on corporate accelerator GenerationS by RVC. The winning team selected by the expert jury will receive a cash prize of 10,000 euro for the development of their project.

The selection of innovative projects began in April 2019. More than 70 start-ups from Russia, Ukraine, Estonia, Kazakhstan, Armenia, Uzbekistan, and India were considered.

Eight teams went to the selection final, offering the most promising solutions in the field of new peptide technologies, oocyte maturation media, 3d technologies bioprinting, decision support systems for specialists of centers of assisted reproductive technologies (ART) and others. Some of the finalists will have an opportunity to continue cooperation with the company at the global level for the further development and implementation of projects.

Recognized specialists in the field of reproductive medicine, prominent representatives of science and business, whose experience makes it possible to assess the prospects of both Russian and international developments, took part in the evaluation of projects.

The expert jury selected the winning team, which will receive 10,000 euro for the development of technology. The project offers unique environments for vitrification of ovarian tissue to preserve fertility and conduct menopausal hormone therapy in patients of different age groups. With the support of leading specialists of the Ferringcompany, the team will be able to bring its decision to a commercial product.

Kirill Litovchenko, CEO of Ferring Pharmaceuticals of Russia and Eurasia
Joining forces with GenerationS, we managed to attract several promising projects in the field of reproductive medicine and fertility. Based on the results of the selection and evaluation, we are pleased to support the project on the development of new methods that will expand the boundaries of the reproductive period and enable women to become the mother of healthy children even after cancer. We will also continue to engage with other selected leaders to help them improve their technologies and introduce new reproductive health solutions.

Ekaterina Petrova, Director of GenerationS Corporate Accelerator
We are delighted that last year we managed to launch a joint project with Ferring, which gave us a new exciting experience, making it possible to dive even deeper into the pharmaceutical industry and understand what technologies can now be in demand on the market. The significance of joint initiative was also in the socially significant direction of scouting — the reproductive area, for which we managed to find earnest worthwhile projects. We hope that the proposed technologies will contribute not only to the development of the company but also to the pharmaceutical industry as a whole



Information

About GenerationS

GenerationS is a platform for the development of corporate innovation, the largest corporate accelerator in Russia and the CIS. Organized by RVC in 2013. GenerationS implements comprehensive programs for the development of corporations: intracorporate — on the development of internal entrepreneurship; acceleration — on scouting and acceleration of external projects; international — to train employees in the methods of building and conducting innovations based on corporations — global leaders.To date, the accelerator infrastructure includes over 16 thousand start-ups from more than 30 countries and about 400 corporate and ecosystem partners. In 2018, GenerationS became the first Russian accelerator accredited by the Global Accelerator Network (GAN), organized by Techstars and became the best corporate accelerator in Europe, according to the Corporate Start-up Summit. In 2019, GenerationS entered the TOP-5 of the best state accelerators in the world, according to UBI Global.
www.generation-startup.ru

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a biopharmaceutical company that seeks, develops and markets innovative products in areas such as reproductive health, oncology, urology, gastroenterology, endocrinology, and orthopedics. A common goal connects the research activities and products of the company — to create specialized medicines that can fight various diseases and pathologies, using the resources and functional potential of the body. Company marketing, medical services, retail and wholesale divisions of the Ferring Company work in almost 60 countries, and management is carried out from the head office in the city of Saint-Preux, Switzerland.
www.ferring.com

Search by name:

Search by date:

Select date in calendar
Select date in calendar
Venue: